샘플 요청 목록

 카트 문의
시장보고서
상품코드
1533790

세계의 식도암 치료제 시장

Esophageal Cancer Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 269 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 식도암 치료제 시장은 2030년까지 194억 달러에 이를 전망

2023년에 127억 달러로 평가된 세계의 식도암 치료제 시장은 2030년에는 194억 달러에 이를 전망이며, 분석 기간 2023년부터 2030년까지 CAGR은 6.2%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 식도 편평상피암 치료제는 CAGR 6.4%로 성장을 지속하고, 분석 기간 종료까지 148억 달러에 달할 것으로 예측됩니다. 식도선암 치료제 부문은 분석 기간 중에 CAGR 5.5%의 성장이 예상됩니다.

미국 시장은 추정 35억 달러, 중국은 CAGR 10.0%로 성장 예측

미국의 식도암 치료제 시장은 2023년 35억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 42억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 10.0%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.6%와 6.2%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 3.9%로 성장할 것으로 예측됩니다.

주요 동향 및 촉진요인

식도암은 특히 침공성이 높은 암으로 수술, 방사선요법, 화학요법, 심지어 표적요법과 면역요법 등 다각적인 치료 접근이 필요하게 되었습니다. 식도암의 약물치료의 기본은 세포독성 화학요법이며, 수술전에 종양을 축소시키기 위해 방사선요법과 병용되거나 진행증례에서는 완화 수단으로 사용됩니다. 최근의 진보에 의해 정상 세포에의 데미지를 최소한으로 억제하면서 암세포를 특이적으로 공격하는 표적 요법이 도입되고 있습니다. 상피성장인자수용체(EGFR), 혈관신생 억제제, 체크포인트 억제제를 표적으로 하는 약제가 임상시험에서 유망시되고 생존율이 개선되어 진행 식도암 환자에게 새로운 희망을 가져오고 있습니다.

식도암 치료제 시장의 성장은 흡연, 비만, 산역류 등 위험인자와 관련된 식도암 발생률 증가 등 여러 요인에 의해 견인되고 있습니다. 유전체 의료의 진보는 개별 종양의 유전자 프로파일에 맞게 개인화 치료 계획의 개발을 촉진하고 치료 효과와 내약성을 향상시킵니다. 면역요법제의 승인은 시장에 큰 영향을 미치며 전통적인 치료법에 반응하지 않는 환자에게 효과적인 옵션을 제공합니다. 또한 제약기업에 의한 연구개발 투자 증가와 암연구기관의 지원이 보다 효과적인 치료법 개발을 뒷받침하고 있습니다. 마지막으로, 일반 시민의 의식 증가와 세계 건강 관리 인프라의 개선은 조기 진단과 조기 치료에 기여하고 시장 성장을 더욱 자극하고 있습니다.

조사 대상 기업 예(주목의 35사)

  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Daiichi Sankyo Co., Ltd.
  • HUTCHMED
  • Innovent Biologics, Inc.
  • Jacobio Pharmaceuticals
  • Merck & Co., Inc.
  • Oncolys BioPharma
  • OncoTherapy Science
  • Rakuten Medical
  • Shanghai Henlius Biotech
  • Shanghai Junshi Biosciences
  • Shionogi, Inc.
  • Taiho Pharmaceutical Co., Ltd.;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.08.22

Global Esophageal Cancer Drugs Market to Reach US$19.4 Billion by 2030

The global market for Esophageal Cancer Drugs estimated at US$12.7 Billion in the year 2023, is expected to reach US$19.4 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2023-2030. Esophageal Squamous-Cell Carcinoma Drugs, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$14.8 Billion by the end of the analysis period. Growth in the Esophageal Adenocarcinoma Drugs segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 10.0% CAGR

The Esophageal Cancer Drugs market in the U.S. is estimated at US$3.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Key Trends and Drivers

Esophageal cancer is a particularly aggressive form of cancer that requires a multifaceted treatment approach, including surgery, radiation, chemotherapy, and increasingly, targeted therapy and immunotherapy. The cornerstone of drug treatment for esophageal cancer involves cytotoxic chemotherapy, which may be used in conjunction with radiation to shrink tumors before surgery or as a palliative measure in advanced cases. Recent advances have introduced targeted therapies that specifically attack cancer cells with minimal damage to normal cells. Drugs targeting the epidermal growth factor receptor (EGFR), angiogenesis inhibitors, and checkpoint inhibitors have shown promise in clinical trials, improving survival rates and offering new hope to patients with advanced esophageal cancer.

The growth in the esophageal cancer drugs market is driven by several factors, including increasing rates of esophageal cancer linked to risk factors such as smoking, obesity, and acid reflux. Advances in genomic medicine have facilitated the development of personalized treatment plans tailored to the genetic profile of individual tumors, enhancing treatment efficacy and tolerability. The approval of immunotherapeutic agents has also significantly impacted the market, providing effective options for patients who do not respond to traditional therapies. Additionally, increased investment in research and development by pharmaceutical companies and support from cancer research organizations are propelling the development of more effective treatment modalities. Lastly, growing public awareness and improving global healthcare infrastructure contribute to earlier diagnosis and treatment, further stimulating market growth.

Select Competitors (Total 35 Featured) -

  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Daiichi Sankyo Co., Ltd.
  • HUTCHMED
  • Innovent Biologics, Inc.
  • Jacobio Pharmaceuticals
  • Merck & Co., Inc.
  • Oncolys BioPharma
  • OncoTherapy Science
  • Rakuten Medical
  • Shanghai Henlius Biotech
  • Shanghai Junshi Biosciences
  • Shionogi, Inc.
  • Taiho Pharmaceutical Co., Ltd.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Esophageal Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Esophageal Cancer and Its Impact on Drug Development
    • Breakthroughs in Immunotherapy for Esophageal Cancer
    • Increasing Role of Genetics in Personalized Cancer Treatments
    • Growth of Targeted Therapy Approaches
    • Influence of Dietary and Lifestyle Factors on Esophageal Cancer Risk
    • Emerging Markets Driving Growth in Cancer Care Infrastructure
    • Regulatory Environment Influencing Drug Approval Processes
    • Advances in Chemotherapy and Radiation Therapy Techniques
    • Collaboration between Biotech and Pharmaceutical Giants
    • Insurance Coverage and Reimbursement Issues Affecting Patient Access
    • Technological Advances in Drug Delivery Systems
    • Clinical Trial Innovations and Their Impact on Treatment Effectiveness
    • Government Policies on Cancer Care and Prevention
    • Safety Concerns and Side Effects of Current Treatment Options
    • Global Health Initiatives and Collaborations for Cancer Control
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Esophageal Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Esophageal Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Esophageal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Esophageal Squamous-Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Esophageal Squamous-Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Esophageal Squamous-Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Esophageal Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Esophageal Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Esophageal Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Targeted Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • JAPAN
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • CHINA
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • EUROPE
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Esophageal Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Esophageal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • FRANCE
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • GERMANY
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Esophageal Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Esophageal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • INDIA
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Esophageal Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Esophageal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Esophageal Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Esophageal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
  • AFRICA
    • Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제